A Single-center, Uncontrolled, Open-label Clinical Trial Evaluating the Pharmacokinetic Characteristics and Safety of Aripiprazole IM Depot in Chinese Patients With Schizophrenia After Multi-dose Administration
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 20 Feb 2019 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Jul 2019.
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.